WORLD TRADE CENTER GREATER PHILADELPHIA | PHILADELPHIA, PA

  • Membership
    • Become a Member
    • Member Success and Feature Stories
  • About Us
    • Meet Our Team
  • Trade Missions and Shows
    • Medica 2024
    • November 3 - 13, 2024: Trade Mission to Spain, Portugal, & Morocco
  • Services
    • International Trade Counseling
    • Export Finance Assistance
    • Educational and Networking Opportunities
    • Trade Service Provider Referrals
  • Programs
    • Selling to the World >
      • Selling to the World: Training Classes
      • Press Release
      • Global Diversity Advisory Council
      • Export Training Program
    • Initiatives >
      • Making Global Local
      • Educational Institution Partnerships
    • Clubs >
      • China Club
  • Events
    • Upcoming Events
    • Signature Events >
      • WTCA's Global Business Forum
      • WTC Day
      • Global Trade Summit
      • Bringing the World to PA
  • Donate
  • Contact
  • Membership
    • Become a Member
    • Member Success and Feature Stories
  • About Us
    • Meet Our Team
  • Trade Missions and Shows
    • Medica 2024
    • November 3 - 13, 2024: Trade Mission to Spain, Portugal, & Morocco
  • Services
    • International Trade Counseling
    • Export Finance Assistance
    • Educational and Networking Opportunities
    • Trade Service Provider Referrals
  • Programs
    • Selling to the World >
      • Selling to the World: Training Classes
      • Press Release
      • Global Diversity Advisory Council
      • Export Training Program
    • Initiatives >
      • Making Global Local
      • Educational Institution Partnerships
    • Clubs >
      • China Club
  • Events
    • Upcoming Events
    • Signature Events >
      • WTCA's Global Business Forum
      • WTC Day
      • Global Trade Summit
      • Bringing the World to PA
  • Donate
  • Contact
Picture

News

Kibow Biotech Continues to Document the "Enteric Dialysis™" Concept With Its Patented Product RENADYL™

11/13/2015

 
Picture
Kibow Biotech is a World Trade Center of Greater Philadelphia Member
NEWTOWN SQUARE, Pa., Nov. 12, 2015 /PRNewswire/ -- This year's annual American society of Nephrology (ASN) 2015 Kidney Week conference was held at the San Diego Convention Center, Nov 3 – 8. Kibow Biotech, Inc. was pleased to mark its 10th year of continuous participation as an exhibitor and to increase awareness and understanding of its "Enteric Dialysis™ or Uremic Toxin Reduction Technology" concept. The company's technology is based on modulating the Gut Microbiome with its dietary supplement product made with the company's technology is based on modulating the Gut Microbiome with its dietary supplement product made with specific strains of Probiotics and selected Prebiotics towards modulation and stabilization of GUT MICROBIOME towards Kidney Failure Problems.
The company also posted its scientific poster abstract presentation at the conference. The abstract summarized cumulative preliminary data from three different pilot/observational scientific human clinical trials, and pharma like validation of its dietary supplement Renadyl™. ​

​
The company also participated in the 3rd World Congress on Targeting Gut Microbiota towards clinical revolution which was held at the Pasteur Institute, Paris from Oct 21-23. Representing Kibow, Dr. Natarajan Ranganathan gave an oral presentation on the same "Enteric Dialysis Concept" and Gut-Kidney connection. The presentation was well received and recognized among all the medical, scientific, and clinical researchers from several countries.
Renadyl™, a probiotic and prebiotic dietary supplement, is currently sold via Kibow's own online store (www.renadyl.com or www.kibowbiotech.com). This probiotic dietary supplement is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology. The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA.

In addition to marketing and sales of Renadyl™ as a dietary supplement, the company is currently exploring the option of advancing the product to prescription drug status by way of adhering to all USFDA guidelines.  This will mandate obtaining the needed Investigator New Drug (IND) process and accomplishing several additional human Randomized Controlled Trials (RCT) in the forthcoming years in USA and possibly in several other countries. As a prescription drug, the product will gain greater acceptance by healthcare professionals and equally increased potential for marketing and sales towards Chronic Kidney Disease applications worldwide.
 
About Kibow Biotech: Established in 1997, Kibow Biotech specializes in research and development of probiotic/prebiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to the governmental rules and regulatory authorities of individual countries.
​
About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

​Investor & Media Contact:
N. Ranganathan 
(610) 353 5130) or Email  
www.kibowbiotech.com 


Original Source

Comments are closed.

    RSS Feed

    Categories

    All
    International Trade News
    Local And Regional News Alerts
    Member News
    Press Releases
    Success Stories
    Wtcgp Events
    Wtcgp In The News
    Wtcgp Newsletters

    Archives

    July 2023
    June 2023
    March 2023
    February 2023
    January 2023
    December 2022
    July 2022
    March 2022
    November 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    July 2019
    June 2019
    May 2019
    April 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    September 2014
    May 2014
    March 2014

Connecting Your Business to the World Starts Here!
​
Whether you have questions about our services or want to explore opportunities for global growth, we’re here to help. Our dedicated team is ready to assist you in navigating the international business landscape.

    How Can We Help You?

Submit
World Trade Center Greater Philadelphia
One Penn Center, Suite 1690
1617 John F Kennedy Blvd.
Philadelphia, 19103
Phone: (215) 586-4240 | [email protected]